Underweight AMGN via trim-not-exit: 25-30% reduction into $415-420, hold residual with $400 trailing stop, await staged re-entry on pullback to $390-410 or breakout above $428 on volume >3M shares.
Underweight AMGN via 25-30% trim into $415-420, holding 70-75% residual with $400 trailing stop. Technical cluster (failed $421.79 breakout, 78% volume contraction, RSI 72.88, 30% three-month rally) warrants de-risking, but Q2 regime change (6 growth drivers, 17 blockbusters, 72% gross margin) and MariTide optionality justify preserving meaningful exposure. Await staged re-entry on $390-410 pullback or $428+ breakout with volume confirmation.
| Position | Action |
|---|---|
| Initial trim: sell 25-30% of AMGN exposure into $415-420 zone via limit orders | Trim 25-30% of position |
| Residual core position: hold 70-75% after trim | Hold 70-75% residual with $400 trailing stop |
| Re-entry on weakness: pullback to $390-410 with RSI cooling toward 55-62 (10 EMA zone) | Stage reloads at 50-75% of trimmed size in $390-410 |
| Re-entry on deeper weakness: price reaches $368 (50 SMA) | Reserve $368 level for higher-conviction re-engagement if breakdown extends |
| Re-entry on strength: confirmed daily close above $428 on volume >3M shares | Re-top residual to more constructive weight as breakout validation |
| Hedge overlay: protect against MariTide binary catalyst risk | Buy protective puts at 380-400 strike, ~quarter duration, sized at 2-3% of position value |
AMGN is a high-quality defensive compounder in a confirmed uptrend with accelerating fundamentals, unpriced pipeline optionality, and a fortress balance sheet—making the risk/reward asymmetrically bullish despite the HOLD ratings from other analysts.
| Indicator | Value | Signal |
|---|---|---|
| close_50_sma | 368.68 | bullish |
| close_200_sma | 345.93 | bullish |
| close_10_ema | 406.15 | bullish |
| macd | 14.52 | bullish |
| rsi | 72.88 | bearish |
| boll_upper | 428.38 | neutral |
| boll_mid | 389.91 | neutral |
| boll_lower | 351.44 | neutral |
| atr | 10.96 | neutral |
| vwma | 396.43 | bullish |
Support: 406.15 · 396.43 · 389.91 · 368.68 · 345.93 | Resistance: 428.38 · 420.26
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price pullback to $390-410 zone with RSI cooling toward 55-62 (10 EMA area)
Then: Stage reloads at 50-75% of trimmed size
RSI overbought reading is a red herring—momentum is accelerating, not rolling over
↩ rebuts: “Bearish argument that overbought RSI signals imminent pullback”
EV: +$440-450 (target on Bollinger upper band breakout at $428.38) · concedes: RSI at 72.88 is technically overbought territory; Valuation appears stretched on TTM metrics (PEG of 2.18); Fair-value model ($371.93) is below current price ($417.84); Volume declining at new highs is a mild concern; Do not chase at current price—preferred entry is pullback to $390-406
Amgen's stock is a "hostage situation" where the bull's case requires everything to go right simultaneously — forward EPS delivering +51%, MariTide succeeding, patent erosion staying manageable, macro remaining benign — while the technical setup shows late-stage momentum exhaustion with RSI at 72.88, distribution-pattern volume, and 12% downside to the 50 SMA at $368 versus 5-7% upside to the $440-450 target.
EV: -$12% (target $368 vs. current $417.84) · concedes: The bull correctly identified declining volume on new highs as a confirmed topping signal; The technical report's language about 'vulnerability to a cool-off rising' and RSI divergence being 'watch closely' is honest and the bear will respect it; The Q2 earnings beat was real in absolute terms — the bear disputes the narrative framing, not the numbers themselves; The bull's 6 growth drivers exist and are contributing revenue — the bear's concern is the erosion of the legacy base offsetting that growth; A surprise Fed cut would be modestly helpful — the bear's point is the base case (86% no cuts) is already priced
→ vs conservative: Conservative framing reads strong-trend signature as reversal signal—RSI at 72.88 without bearish divergence is a late-stage thrust, not a top; 50-day SMA at 368 creates worse entry than current levels if breakout above 428 fires
→ vs conservative: The trim size is too aggressive—protecting from a 5% pullback costs the 20-40% upside if MariTide hits; terrible asymmetry
→ vs conservative: Model fair value at 371.93 doesn't capture 51% EPS expansion, expanding margins, deleveraging tailwinds, and defensive beta; questioning the model, not the stock
→ vs neutral: Trailing stop at 400 locks in 60-70% of position but still gives up most asymmetric upside—a hold should either be full conviction or full trim, not the worst of both worlds
AMGN is in a powerful medium-term uptrend with all timeframes bullish (Golden Cross intact since late May), but near-term risk/reward is poor given overbought RSI (72.88), price extended ~13% above the 50 SMA, and thinning volume at the highs. MACD remains bullish and expanding (14.52 with histogram +2.43), and ATR has risen ~46% to 10.96, warranting wider stop losses. The preferred trading action is HOLD for existing positions with trailing stops below the 10 EMA (~$406), while fresh entries should await either a breakout above $428.38 on renewed volume or a pullback to the $390–406 support zone.
Market Capitalization
$226.05B
TTM Revenue
$38.09B
TTM Net Income
$8.74B
TTM EPS (Diluted)
$16.11
Forward EPS
$24.28
TTM P/E
25.94x
Forward P/E
17.21x
PEG Ratio
2.18
Price to Book
19.33x
Dividend Yield
2.43%
Beta
0.413
52-Week High
$421.79
52-Week Low
$269.77
50-Day Avg Price
$366.89
200-Day Avg Price
$348.13
Book Value / Share
$21.62
Revenue FY2022
$26.32B
Revenue FY2023
$28.19B
Revenue FY2024
$33.42B
Revenue FY2025
$36.75B
Diluted EPS FY2022
$12.11
Diluted EPS FY2023
$12.49
Diluted EPS FY2024
$7.56
Diluted EPS FY2025
$14.23
Net Income FY2024
$4.09B
Net Income FY2025
$7.71B
Q2 2026 Revenue
$10.05B
Q2 2026 Diluted EPS
$4.37
Q2 2026 Gross Margin
72.0%
Q2 2026 Operating Income
$3.51B
Gross Margin TTM
71.9%
Operating Margin TTM
35.5%
Net Margin TTM
23.0%
EBITDA Margin TTM
45.3%
Return on Equity
91.5%
Return on Assets
8.7%
Cost of Revenue FY2025
$12.04B
R&D FY2025
$7.27B
SG&A FY2025
$7.05B
Interest Expense FY2025
$2.76B
TTM Free Cash Flow
$8.65B
FCF Margin TTM
22.7%
CapEx FY2025
$1.86B
CapEx / Revenue
~5%
FY2025 Operating Cash Flow
$9.96B
Q2 2026 Free Cash Flow
$3.49B
Total Assets Q2 2026
$95.6B
Total Liabilities Q2 2026
$84.0B
Stockholders' Equity Q2 2026
$11.7B
Total Debt Q2 2026
$57.3B
Cash & Equivalents Q2 2026
$14.0B
Net Debt Q2 2026
$43.3B
Goodwill
$18.7B
Other Intangibles
$20.5B
Current Ratio Q2 2026
1.37
Net Debt / EBITDA
~2.5x
Interest Coverage
~6.4x
Dividends Paid FY2022
$4.20B
Dividends Paid FY2023
$4.56B
Dividends Paid FY2024
$4.83B
Dividends Paid FY2025
$5.12B
Buybacks FY2022
$6.36B
Buybacks FY2023
$0.00B
Buybacks FY2024
$0.20B
Buybacks FY2025
$0.00B
Annualized Dividend
~$9.46/share
Horizon Deal Value
~$27.9B
Strengths
Concerns
Amgen is a high-quality, mega-cap ($226B) biotechnology company with a diversified portfolio spanning oncology, inflammation, cardiovascular, and rare diseases, significantly enhanced by the $27.9B Horizon Therapeutics acquisition (Q4 2023). The post-integration story is compelling: Q2 2026 demonstrated record revenue of $10.05B with best-in-class 72% gross margin and 35.5% operating margin, while TTM EPS of $16.11 is expected to surge to $24.28 (+51%) driven by operating leverage as Horizon assets scale. The balance sheet shows disciplined deleveraging (net debt reduced ~$10B from peak to $43.3B, net debt/EBITDA ~2.5x) while maintaining a robust $8.65B TTM free cash flow that comfortably funds the growing dividend (~$9.46/share annualized) with excess for buybacks. With a defensive 0.41 beta, 2.43% yield, and reasonable 17.2x forward P/E, Amgen suits long-term income and growth investors; however, near-52-week-high pricing and patent cliff risks (2025-2027) warrant caution for new entries, with pullbacks to $340-355 offering better risk-reward. HOLD recommended for existing positions.
Macro: Risk-on regime intact: S&P 500 closed at record high on 8/12; TSX also at fresh record; indices ended higher 8/13 on weak producer inflation + lower crude. Disinflationary data flow (benign CPI/PPI prints) reduced rate-hike bets per Reuters/AFP; yields rolled lower on the week. Fed Funds, CPI, 10Y, and Unemployment FRED series unavailable (no API key). Prediction markets show 86% probability of NO Fed rate cuts in 2026 (–1.9pp w/w) — aggressive-easing tail-risk effectively priced out; 8% probability of US recession by end-2026 (–1.0pp w/w) — soft-landing/expansion base case. A no-cuts, no-recession, falling-yield regime is neutral-to-supportive for AMGN: caps multiple-expansion tailwind a cut cycle would deliver but removes growth-scare risk that would compress pharma multiples. GLP-1/obesity coverage keeps cardiometabolic category (Repatha) topical as indirect halo.